Large gap with delayed quotes
|
Last quote
12/26/2024 -
20:00:00
|
Bid
12/27/2024 -
04:05:56
|
Bid Volume |
Ask
- -
-
|
Ask Volume |
|---|---|---|---|---|
|
34.37
+0.18
(
+0.53% )
|
14.10
|
100 |
-
|
- |
Analysis date: 24.12.2024
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 20.12.2024.
Interest
Weak
Weak
Weak interest since 20.12.2024.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 29.11.2024 at a price of 59.39.
Evaluation
Strongly undervalued
Strongly undervalued
Based on its growth potential and our own criteria, at its current price the stock is strongly undervalued.
MT Tech Trend
Negative
Negative
The forty day Medium Term Technical Trend is negative since 10.12.2024. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is
4wk Rel Perf
-41.43%
-41.43%
The four week relative underperformance versus SP500 is 41.43%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 10.12.2024.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.32%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.51%.
Mkt Cap in $bn
2.02
2.02
With a market capitalization between $2 & $8bn, AGIOS PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
1.28
1.28
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
37.81
37.81
The estimated PE is for the year 2028.
LT Growth
48.36%
48.36%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
7
7
Over the last seven weeks, an average of 7 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
260
260
For 1% of index variation, the stock varies on average by 2.60%.
Correlation
0.41
0.41
41.14% of stock movements are explained by index variations.
Value at Risk
8.21
8.21
The value at risk is estimated at USD 8.21. The risk is therefore 24.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
19.09.2014
19.09.2014